Chemistry:Technetium (99mTc) sulesomab

From HandWiki
Short description: Chemical compound


Technetium (99mTc) sulesomab
Monoclonal antibody
TypeFab' fragment
SourceMouse
TargetNCA-90 (granulocyte cell antigen)
Clinical data
ATC code
Legal status
Legal status
  • AU: Approved
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒N☑Y (what is this?)  (verify)

Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]

References

  1. ↑ "WHO Drug Information". http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list75.pdf. 
  2. ↑ "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice 17 (6): 447–52. 2008. doi:10.1159/000151565. PMID 18836272. 
  3. ↑ "Mechanism of accumulation of 99mTc-sulesomab in inflammation". Journal of Nuclear Medicine 44 (1): 11–8. January 2003. PMID 12515870. http://jnm.snmjournals.org/content/44/1/11. Retrieved 2019-12-10. 
  4. ↑ EMEA: Summary of product characteristics (LeukoScan)
  5. ↑ "Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging 60 (4): 413–23. December 2016. PMID 25325395. 
  6. ↑ "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine 29 (12): 781–5. December 2004. doi:10.1097/00003072-200412000-00001. PMID 15545877. 
  7. ↑ "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice 17 (6): 447–52. 2008. doi:10.1159/000151565. PMID 18836272. 
  8. ↑ "Technetium-99m (99mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology 272 (6): 1377–82. June 2015. doi:10.1007/s00405-014-2938-1. PMID 24534898. 
  9. ↑ "Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections". Nuclear Medicine Communications 26 (6): 489–96. June 2005. doi:10.1097/00006231-200506000-00003. PMID 15891591. 
  10. ↑ "Products" (in en-US). https://www.immunomedics.com/our-science/products/. 

See also




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Technetium_(99mTc)_sulesomab&oldid=2600280"